5 Scopus citations

Abstract

Purpose/Background Venlafaxine is a commonly used antidepressant with both serotonergic and noradrenergic activity. There are concerns that it may prolong the corrected QT interval (QTc), and older adults may be at higher risk for this adverse effect, especially at higher dosages of the medication. Methods/Procedures In this secondary analysis of a prospective clinical trial, we measured changes in QTc and other electrocardiogram (ECG) parameters in 169 adults 60 years or older with a major depressive disorder treated acutely with venlafaxine extended release up to 300 mg daily. We examined the relationship of venlafaxine dosage and ECG parameters, as well as the relationship between serum levels of venlafaxine and ECG parameters. Findings/Results Venlafaxine exposure was not associated with an increase in QTc. Heart rate increased with venlafaxine treatment, whereas the PR interval shortened, and QRS width did not change significantly. The QTc change from baseline was not associated with venlafaxine dosages or serum concentrations. Age, sex, cardiovascular comorbidities, and depression remission status did not predict changes in QTc with venlafaxine. Implications/Conclusions Venlafaxine treatment did not prolong QTc or other ECG parameters, even in high dosages in older depressed adults. These findings indicate that venlafaxine does not significantly affect cardiac conduction in most older patients.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume40
Issue number6
DOIs
StatePublished - Nov 1 2020

Keywords

  • ECG
  • QTc
  • late life depression
  • serum levels
  • venlafaxine

Fingerprint

Dive into the research topics of 'The Effect of Venlafaxine on Electrocardiogram Intervals during Treatment for Depression in Older Adults'. Together they form a unique fingerprint.

Cite this